490 related articles for article (PubMed ID: 21619513)
1. Sterol 14alpha-demethylase (CYP51) as a therapeutic target for human trypanosomiasis and leishmaniasis.
Lepesheva GI; Waterman MR
Curr Top Med Chem; 2011; 11(16):2060-71. PubMed ID: 21619513
[TBL] [Abstract][Full Text] [Related]
2. In vitro evaluation of arylsubstituted imidazoles derivatives as antiprotozoal agents and docking studies on sterol 14α-demethylase (CYP51) from Trypanosoma cruzi, Leishmania infantum, and Trypanosoma brucei.
Rojas Vargas JA; López AG; Pérez Y; Cos P; Froeyen M
Parasitol Res; 2019 May; 118(5):1533-1548. PubMed ID: 30903349
[TBL] [Abstract][Full Text] [Related]
3. Substrate preferences and catalytic parameters determined by structural characteristics of sterol 14alpha-demethylase (CYP51) from Leishmania infantum.
Hargrove TY; Wawrzak Z; Liu J; Nes WD; Waterman MR; Lepesheva GI
J Biol Chem; 2011 Jul; 286(30):26838-48. PubMed ID: 21632531
[TBL] [Abstract][Full Text] [Related]
4. Complexes of Trypanosoma cruzi sterol 14α-demethylase (CYP51) with two pyridine-based drug candidates for Chagas disease: structural basis for pathogen selectivity.
Hargrove TY; Wawrzak Z; Alexander PW; Chaplin JH; Keenan M; Charman SA; Perez CJ; Waterman MR; Chatelain E; Lepesheva GI
J Biol Chem; 2013 Nov; 288(44):31602-15. PubMed ID: 24047900
[TBL] [Abstract][Full Text] [Related]
5. An Overview on Target-Based Drug Design against Kinetoplastid Protozoan Infections: Human African Trypanosomiasis, Chagas Disease and Leishmaniases.
Kourbeli V; Chontzopoulou E; Moschovou K; Pavlos D; Mavromoustakos T; Papanastasiou IP
Molecules; 2021 Jul; 26(15):. PubMed ID: 34361781
[TBL] [Abstract][Full Text] [Related]
6. Structural characterization of CYP51 from Trypanosoma cruzi and Trypanosoma brucei bound to the antifungal drugs posaconazole and fluconazole.
Chen CK; Leung SS; Guilbert C; Jacobson MP; McKerrow JH; Podust LM
PLoS Negl Trop Dis; 2010 Apr; 4(4):e651. PubMed ID: 20386598
[TBL] [Abstract][Full Text] [Related]
7. Sterol 14α-Demethylase Structure-Based Optimization of Drug Candidates for Human Infections with the Protozoan Trypanosomatidae.
Friggeri L; Hargrove TY; Rachakonda G; Blobaum AL; Fisher P; de Oliveira GM; da Silva CF; Soeiro MNC; Nes WD; Lindsley CW; Villalta F; Guengerich FP; Lepesheva GI
J Med Chem; 2018 Dec; 61(23):10910-10921. PubMed ID: 30451500
[TBL] [Abstract][Full Text] [Related]
8. Crystal structures of Trypanosoma brucei sterol 14alpha-demethylase and implications for selective treatment of human infections.
Lepesheva GI; Park HW; Hargrove TY; Vanhollebeke B; Wawrzak Z; Harp JM; Sundaramoorthy M; Nes WD; Pays E; Chaudhuri M; Villalta F; Waterman MR
J Biol Chem; 2010 Jan; 285(3):1773-80. PubMed ID: 19923211
[TBL] [Abstract][Full Text] [Related]
9. Sterol 14alpha-demethylase as a potential target for antitrypanosomal therapy: enzyme inhibition and parasite cell growth.
Lepesheva GI; Ott RD; Hargrove TY; Kleshchenko YY; Schuster I; Nes WD; Hill GC; Villalta F; Waterman MR
Chem Biol; 2007 Nov; 14(11):1283-93. PubMed ID: 18022567
[TBL] [Abstract][Full Text] [Related]
10. Sterol 14α-Demethylase from Trypanosomatidae Parasites as a Promising Target for Designing New Antiparasitic Agents.
da Silva Santos-Júnior PF; Schmitt M; de Araújo-Júnior JX; da Silva-Júnior EF
Curr Top Med Chem; 2021; 21(21):1900-1921. PubMed ID: 33655860
[TBL] [Abstract][Full Text] [Related]
11. Structural complex of sterol 14α-demethylase (CYP51) with 14α-methylenecyclopropyl-Delta7-24, 25-dihydrolanosterol.
Hargrove TY; Wawrzak Z; Liu J; Waterman MR; Nes WD; Lepesheva GI
J Lipid Res; 2012 Feb; 53(2):311-20. PubMed ID: 22135275
[TBL] [Abstract][Full Text] [Related]
12. The kinetoplastid chemotherapy revisited: current drugs, recent advances and future perspectives.
Castillo E; Dea-Ayuela MA; Bolás-Fernández F; Rangel M; González-Rosende ME
Curr Med Chem; 2010; 17(33):4027-51. PubMed ID: 20939823
[TBL] [Abstract][Full Text] [Related]
13. A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection.
Doyle PS; Chen CK; Johnston JB; Hopkins SD; Leung SS; Jacobson MP; Engel JC; McKerrow JH; Podust LM
Antimicrob Agents Chemother; 2010 Jun; 54(6):2480-8. PubMed ID: 20385875
[TBL] [Abstract][Full Text] [Related]
14. Parasitology. Drugs to combat tropical protozoan parasites.
Gelb MH; Hol WG
Science; 2002 Jul; 297(5580):343-4. PubMed ID: 12130767
[No Abstract] [Full Text] [Related]
15. In vitro and in vivo studies of the antiparasitic activity of sterol 14α-demethylase (CYP51) inhibitor VNI against drug-resistant strains of Trypanosoma cruzi.
Soeiro Mde N; de Souza EM; da Silva CF; Batista Dda G; Batista MM; Pavão BP; Araújo JS; Aiub CA; da Silva PB; Lionel J; Britto C; Kim K; Sulikowski G; Hargrove TY; Waterman MR; Lepesheva GI
Antimicrob Agents Chemother; 2013 Sep; 57(9):4151-63. PubMed ID: 23774435
[TBL] [Abstract][Full Text] [Related]
16. CYP51 as drug targets for fungi and protozoan parasites: past, present and future.
Lepesheva GI; Friggeri L; Waterman MR
Parasitology; 2018 Dec; 145(14):1820-1836. PubMed ID: 29642960
[TBL] [Abstract][Full Text] [Related]
17. Successful Aspects of the Coadministration of Sterol 14α-Demethylase Inhibitor VFV and Benznidazole in Experimental Mouse Models of Chagas Disease Caused by the Drug-Resistant Strain of Trypanosoma cruzi.
Guedes-da-Silva FH; Batista DDGJ; Da Silva CF; Pavão BP; Batista MM; Moreira OC; Souza LRQ; Britto C; Rachakonda G; Villalta F; Lepesheva GI; Soeiro MNC
ACS Infect Dis; 2019 Mar; 5(3):365-371. PubMed ID: 30625275
[TBL] [Abstract][Full Text] [Related]
18. Trypanocidal activity of nitroaromatic prodrugs: current treatments and future perspectives.
Wilkinson SR; Bot C; Kelly JM; Hall BS
Curr Top Med Chem; 2011; 11(16):2072-84. PubMed ID: 21619510
[TBL] [Abstract][Full Text] [Related]
19. VFV as a New Effective CYP51 Structure-Derived Drug Candidate for Chagas Disease and Visceral Leishmaniasis.
Lepesheva GI; Hargrove TY; Rachakonda G; Wawrzak Z; Pomel S; Cojean S; Nde PN; Nes WD; Locuson CW; Calcutt MW; Waterman MR; Daniels JS; Loiseau PM; Villalta F
J Infect Dis; 2015 Nov; 212(9):1439-48. PubMed ID: 25883390
[TBL] [Abstract][Full Text] [Related]
20. Anilinoquinoline based inhibitors of trypanosomatid proliferation.
Ferrins L; Sharma A; Thomas SM; Mehta N; Erath J; Tanghe S; Leed SE; Rodriguez A; Mensa-Wilmot K; Sciotti RJ; Gillingwater K; Pollastri MP
PLoS Negl Trop Dis; 2018 Nov; 12(11):e0006834. PubMed ID: 30475800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
